Congress schedules xylazine but gives manufacturers a year to comply
S. 545 — Combating Illicit Xylazine Act · Filed by Catherine Cortez Masto (D-NV) · 35 cosponsors · Introduced Feb 12, 2025 · Reported out
Your members of Congress
Enter a ZIP to see where your representative and both senators stood on this bill.
Looked up on this device — your ZIP is never stored on our servers.
What it does
This bill adds xylazine (a veterinary sedative increasingly diverted to illicit drug markets) to Schedule III of the Controlled Substances Act, making unauthorized possession a federal crime. It permits veterinarians and pharmacies to dispense xylazine to animal owners and government animal-control programs without triggering user registration, and gives manufacturers and practitioners a grace period (1 year for labeling, 60 days for registration) to comply with new security and recordkeeping rules before enforcement begins.
Why we flagged it
The bill's core function is to place xylazine under federal drug control and establish reporting requirements on its illicit prevalence. It is a public-health and law-enforcement measure, not a market-facing carve-out or subsidy.
What the text implies
- Grace periods (60 days for practitioner registration, 1 year for labeling/packaging) create a compliance window during which existing manufacturers and veterinary practitioners may continue operations under old rules, potentially delaying enforcement and allowing continued diversion.
- The bill exempts manufacturers from capital expenditure requirements for Schedule III security infrastructure, shifting compliance burden to smaller or newer entrants and potentially creating competitive advantage for incumbent manufacturers.
The full analysis lists 4 implications of this text.
Who stands to gain
existing xylazine manufacturers (exempted from capital expenditure requirements); veterinary pharmaceutical suppliers; law enforcement agencies (expanded enforcement authority)